In this study, researchers from Turkey compared 2 treatments in patients with untreated hepatitis B e antigen (HBeAg) positive chronic hepatitis B virus (HBV) infection. They compared a combination therapy of interferon (IFN)-alpha-2b and lamivudine, and IFN-alpha-2b monotherapy.
The team evaluated 33 patients who received therapy with lamivudine (100mg daily) and IFN-alpha-2b (10 million U 3 times per week) for 12 months. They also assessed 16 patients who received IFN-alpha-2b alone.
|Both therapies were well tolerated.|
|Clinical Infectious Diseases|
The primary end point was sustained suppression of HBV DNA and HBeAg seroconversion. The team observed this in 45% of the combination therapy group and in 19% of the monotherapy group.
The researchers found that both therapies were well tolerated.
Dr Kendal Yalcin's team concluded, "Combination therapy increased the rate of sustained suppression of HBeAg and resulted in significant improvement in Knodell histologic activity index scores, compared with monotherapy".
"However, there was no significant difference in rates of sustained suppression between the 2 groups at the end of follow-up".